Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00426660 · ClinicalTrials.gov registry record · Phase 3
Expanded Access Program for Maraviroc At Multiple Centers
A Phase 3 study of HIV Infections, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,047
- Enrollment target
- 20
- Study locations
NCT00426660 is a Phase 3 study of HIV Infections that has completed, run by ViiV Healthcare. The registered enrollment target is 1,047 participants, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (136% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00426660, a Phase 3 study of HIV Infections, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,047 participants
- Enrollment target
- 20
- Study locations
Study Summary
To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
Conditions Studied
Interventions
- DRUG maraviroc
Study Locations (20)
California
- Vista Medical - Beverly Hills
- AHF Research Center - Beverly Hills
- Orange County Center for Special Immunology - Fountain Valley
- Kaiser Permanente - Hayward
- Living Hope Clinical Trials - Long Beach
- AltaMed Health Services Corporation - Los Angeles
- Kaiser Permanente Medical Center - Los Angeles
- Robert Bolan, MD - Los Angeles
- Maternal-Child and Adolescent Clinic of Infectious Diseases and Virology - Los Angeles
- Peter J. Ruane, M.D. Inc. - Los Angeles
- Synergy Hematology-Oncology Associates - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- Erlmed Corp ABA Lim-Keith Muiltispecialty Clinic Inc. - Los Angeles
- Office of Anthony Mills, MD - Los Angeles
- Office of Dr. Salah Bibi, MD - Modesto
Alabama
- The University of Alabama - Birmingham
- Health Services Center - Hobson City
Arkansas
- Health for Life Clinic PLLC - Little Rock
- Thomas T Jefferson, MD - Little Rock
Arizona
- El Rio, Special Immunology Associates - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,047 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00426660
The ClinicalTrials.gov registry entry for NCT00426660 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,047 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 444-participant average among 542 other HIV Infections trials with a reported enrollment target (136% higher). The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which maraviroc is the first listed.
NCT00426660 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00426660 about?
NCT00426660 is a clinical study titled "Expanded Access Program for Maraviroc At Multiple Centers". To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.
What is the current status of trial NCT00426660?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,047 participants. The study started on 2007-02. Estimated completion is 2010-06.
What conditions does trial NCT00426660 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00426660?
The interventions under investigation include: maraviroc (DRUG).
Who is sponsoring clinical trial NCT00426660?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00426660 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.